BioXcel Therapeutics, Inc. Overview
Pro stress-test →BioXcel Therapeutics is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. The company's lead product IGALMI is a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company plans to submit an sNDA in early Q1 2026 seeking FDA approval for at-home use of IGALMI for agitation associated with bipolar disorders or schizophrenia.
Strategic Profile
Pro stress-test →The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications. Its wholly owned subsidiary, OnkosXcel Therapeutics, is focused on the development of medicines in immuno-oncology. The company targets a large market opportunity with an estimated 57-77 million annual at-home agitation episodes in the U.S.
Competitive Landscape
Pro stress-test →BioXcel positions IGALMI as an at-home treatment option where there are currently no FDA-approved options. The company competes in the neuropsychiatric agitation treatment market against hospital and emergency-based care settings, as well as emerging digital health solutions for acute psychiatric conditions.
Industry Context
BioXcel Therapeutics, Inc. operates in Biopharmaceutical (Neuroscience & Immuno-Oncology).
Key facts
Founded: 2014 · Headquarters: New Haven, United States · Revenue: $0.752M · Market cap: $38.71M